Divi’s Laboratories reported consolidated net revenue elevated virtually 68% to ₹538 crore for the quarter ended March 2024 on the again of a income from operations that was 18% greater. Revenue from operations of the lively pharmaceutical substances, intermediates and nutraceutical substances maker elevated to ₹2,303 crore (₹1,951 crore). The firm had posted ₹321 crore net revenue within the 12 months earlier.
The firm has declared a last dividend of ₹30 per fairness share of face worth ₹2 every for 2023-24. For the total fiscal, it reported consolidated income from operations elevated to ₹7,845 crore (₹7,767 crore) whereas net revenue declined to ₹1,600 crore (₹1,824 crore).
